Synthetic Biologics, Inc. (NYSEAMERICAN:SYN – Get Free Report)’s stock price was up 1% during trading on Monday . The company traded as high as $1.02 and last traded at $1.02. 57,700 shares traded hands during trading, a decline of 71% from the average daily volume of 197,338 shares. The stock had previously closed at $1.01.
Synthetic Biologics Price Performance
The company has a market capitalization of $16.16 million, a price-to-earnings ratio of -0.84 and a beta of 1.38.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Featured Stories
- Five stocks we like better than Synthetic Biologics
- ESG Stocks, What Investors Should Know
- The Average 401k Balance by Age Explained
- How to Calculate Stock Profit
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- The Role Economic Reports Play in a Successful Investment Strategy
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
